Ultime notizie per Jaguar Health (NASDAQ:JAGX) Azioni

Jaguar Health

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

As recently <a href="https://jaguarhealth.gcs-web.com/news-releases/news-release-details/proof-concept-results-show-crofelemer-reduced-total-parenteral">announced</a>, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome patient by up to 12.5%
The first two patients in this IIT were taken off crofelemer after 12 weeks of treatment for a period intended to last 30 days, per the study protocol, but were promptly placed back on daily crofelemer treatment because their symptoms worsened
Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's intestinal failure products, resulting in non-dilutive funding for Jaguar
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 30, 2025 / <a href="https://pr.report/bxg0">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) family companies <a href="https://pr.report/bxg2">Napo Pharmaceuticals</a> (Napo) and <a href="https://pr.report/bxg3">Napo Therapeutics</a> today announced that initial proof-of-concept results show that a novel liquid formulation of crofelemer reduced the required total parenteral nutrition (TPN) and supplementary intravenous fluids in a third intestinal failure patient. This is the second pediatric patient with intestinal failure due to the orphan disease short bowel syndrome (SBS-IF) who was treated with crofelemer. To date, three patients with intestinal failure due to SBS-IF or microvillus inclusion disease (MVID) have been treated with crofelemer in this exploratory, single-arm open label non-randomized IIT in Abu Dhabi.

News

JAGX

Jaguar Health's Napo Announces That Initial Proof-Of-Concept Results From Ongoing IIT Show Liquid Formulation Of Crofelemer Reduced Required TPN And Supplementary Intravenous Fluids In Third Intestinal Failure Patient

Biotech

General

Jaguar Health And Napo therapeutics Announce Initial Proof-Of-Concept Results Showing Liquid Formulation Of Crofelemer Reduced Total Parenteral Nutrition In Third Intestinal Failure Orphan Disease Patient

Jaguar Health Board Unanimously Authorizes Company To Include Cryptocurrency As Treasury Reserve Asset

Canalevia&#xAE; (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogs
Jaguar is exploring the possibility of approval of Canalevia for treatment of general diarrhea in dogs in the EU based on the statistically significant data from a completed study
Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common reason for visits to the veterinary emergency hospital, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs
Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia to regulatory approval and commercialization for general diarrhea globally
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 25, 2025 / <a href="https://pr.report/bt7v">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar), under its Jaguar Animal Health tradename for the veterinary market, today announced that the company plans to pursue approval from the European Medicines Agency's (EMA) <a href="https://pr.report/bt7x">Committee for Veterinary Medicinal Products</a> (CVMP) for Canalevia (crofelemer delayed-release tablets) in the European Union for treatment of general diarrhea in dogs. Canalevia, under the name <a href="https://pr.report/bt7y">Canalevia-CA1</a>, is conditionally approved by the U.S. Food and Drug Administration (FDA) as a prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs.

Jaguar Health Pursues EU Approval For Canalevia To Treat General Dog Diarrhea

<a href="https://pr.report/bsl6">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) ("Jaguar" or "the Company"), announced today that the maturity date has been extended from June 30, 2025 to January 30, 2026 for approximately $2.57 million aggregate principal amount of convertible promissory notes originally issued by the Company as part of the previously announced $3.448 million bridge financing that closed on March 31, 2025. Prior to the extension, five investors converted $0.866 million (including accrued interest) of the original bridge financing into equity in the Company.
"We're very pleased with each of the participants in this bridge financing that agreed to the extension of the maturity date," said Lisa Conte, Jaguar's Founder and CEO. "Each of these investors is committed to helping provide the resources needed to support Jaguar's goal of forging corporate partnerships to bring in non-dilutive funding for the Company's three core development programs for crofelemer, our novel plant-based prescription medicine: our orphan disease intestinal failure program; our ongoing efforts to make crofelemer available for treatment of cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies; and our ongoing development program to expand access for <a href="https://pr.report/bsl8">Canalevia</a>&#xAE; (crofelemer delayed-release tablets) in dogs from the conditional approval in chemotherapy-induced diarrhea to a potential global approval for acute general diarrhea."

Jaguar Health Announces Maturity Date Has Been Extended From June 30, 2025 To January 30, 2026 For ~$2.57M Aggregate Principal Amount Of Convertible Promissory Notes Originally Issued By Company As Part Of Previously Announced $3.448M Bridge Financing

Enrollment in company's first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached approximately 25%
As recently <a href="https://jaguarhealth.gcs-web.com/news-releases/news-release-details/proof-concept-results-show-crofelemer-reduced-total-parenteral">announced</a>, initial proof-of-concept results of the ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in patients with intestinal failure due to MVID and short bowel syndrome by up to 27% and 12.5% respectively; data from the third patient enrolled is expected
Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's intestinal failure products, resulting in non-dilutive funding for Jaguar
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 23, 2025 / <a href="https://pr.report/bqbi">Jaguar Health, Inc.</a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) today provided updates on the company's orphan disease intestinal failure program. Jaguar, through Jaguar family companies <a href="https://pr.report/bqbk">Napo Pharmaceuticals</a> (Napo) and <a href="https://pr.report/bqbl">Napo Therapeutics</a>, is currently supporting two independent proof-of-concept investigator-initiated trials (IITs), and conducting two placebo-controlled Phase 2 studies, of crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, in patients with intestinal failure due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) in the United States, European Union, and/or Middle East/North Africa regions.
Completion of Napo's randomized double-blind, placebo-controlled Phase 2 study of crofelemer in pediatric MVID patients is expected in mid-2026 as planned.

Jaguar Health Updates On Orphan Disease Intestinal Failure Program; Completion Of Napo's Phase 2 Study Of Crofelemer In Pediatric MVID Patients Is Expected In Mid-2026 As Planned

Productive and collaborative discussion on proposed pathway by the company to bring crofelemer to approval for cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies
The currently estimated US metastatic breast cancer population would qualify as an orphan population, which aligns with company's core focus on orphan diseases
Company plans to promptly pursue authorization to initiate expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 9, 2025 / <a href="https://pr.report/ba6y">Jaguar Health, Inc.</a><a href="https://pr.report/ba7e">(NASDAQ:</a><a href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) family company Napo Pharmaceuticals (Napo) today provided a recap on the company's assessment of the in-person Type C Meeting on May 28, 2025 with the Division of Gastroenterology of the U.S. Food and Drug Administration (FDA) to discuss the statistically significant responder analysis results for adult patients with breast cancer in Napo's recently conducted Phase 3 <a href="https://pr.report/ba6z">OnTarget</a> trial.

Jaguar Health's Napo Pharma Advances Crofelemer For Cancer Therapy-Related Diarrhea Following FDA Type C Meeting

<h3>Gainers</h3>
<ul>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares increased by 72.6% to $0.47 during Wednesday's regular session. The company's market cap stands at $68.5 million. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares rose 26.8% to $19.3. The company's market cap stands at $116.2 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock rose 25.16% to $0.39. The company's market cap stands at $2.9 million. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) stock rose 24.53% to $1.32. The company's market cap stands at $65.8 million. </li>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) stock moved upwards by 23.0% to $6.55. The company's market cap stands at $7.2 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) stock moved upwards by 20.6% to $2.61. The company's market cap stands at $6.6 million. As per the news, the Q1 earnings report came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares decreased by 41.4% to $0.07 during Wednesday's regular session. The company's, Q1 earnings came out 4 days ago. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares decreased by 22.09% to $4.55. The company's market cap stands at $3.0 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 18.56% to $0.01. The company's, Q1 earnings came out yesterday. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock decreased by 16.05% to $0.18. The market value of their outstanding shares is at $5.2 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>ABVC BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVC#NASDAQ">ABVC</a>) stock declined by 13.87% to $1.18. The market value of their outstanding shares is at $19.7 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares decreased by 12.58% to $1.46. The company's market cap stands at $4.1 million. The company's, Q1 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ABVC

AKYA

APLM

APVO

BDSX

EYEN

GTBP

HCTI

KDLY

KLTO

PTPI

12 Health Care Stocks Moving In Wednesday's Intraday Session

WIIM

Jaguar Health shares are trading lower after the company announced the pricing of a $1.5 million registered direct offering of 246,306 shares at $6.09 per share.

<a href="https://pr.report/amzv">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) ("Jaguar" or "the Company"), today announced that it has entered into definitive agreements for the purchase and sale of 246,306 shares of common stock at a purchase price of $6.09 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company agreed to issue to investors unregistered warrants to purchase up to 492,612 shares of common stock at an exercise price of $5.84 per share that will be immediately exercisable upon issuance and will expire on the earlier of (i) 24 months from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event. The closing of the offering is expected to occur on or about May 22, 2025, subject to the satisfaction of customary closing conditions.
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.
The gross proceeds to the Company from the offering are expected to be approximately $1.5 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for general corporate purposes, including growth capital, working capital, operating expenses, repayment of outstanding convertible promissory notes that are not converted into Common Stock by holders, and capital expenditures.

Offerings

Jaguar Health Prices $1.5M Registered Direct Offering Of 246,306 Shares At A Price Of $6.09/Share

As <a href="https://jaguarhealth.gcs-web.com/news-releases/news-release-details/proof-concept-results-show-crofelemer-reduced-total-parenteral">announced</a>, initial proof-of-concept (POC) results from distinct ongoing investigator-initiated trial (IIT) in Abu Dhabi show crofelemer reduced total parenteral support in a pediatric MVID patient with intestinal failure by up to 27%; per the IIT protocol, patient was taken off crofelemer after 12 weeks of treatment for a period of 30 days, but was restarted on daily crofelemer treatment after just 8 days, as patient's symptoms were worsening
Additional POC IIT results expected throughout 2025 for MVID; results from company's MVID Phase 2 study expected with completion of treatment in H2 2026
Ground-breaking results in single-digit number of MVID patients could potentially lead to expedited approval in the EU through <a href="https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines">PRIME</a> and to <a href="https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy">Breakthrough Therapy</a> designation in the US
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / May 20, 2025 / <a href="https://pr.report/als3">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) family companies <a href="https://pr.report/als5">Napo Pharmaceuticals, Inc.</a> (Napo) and <a href="https://pr.report/als6">Napo Therapeutics S.p.A.</a> today announced that the first patient has been randomized in Napo's randomized, double-blind, placebo-controlled Phase 2 clinical trial to evaluate the safety and efficacy of the novel crofelemer oral powder for solution formulation in pediatric patients with intestinal failure due to the ultrarare disease MVID.
Patients with MVID suffer from devastating diarrhea and dehydration caused by this debilitating, lifelong condition. These pediatric patients often require lifelong and life-sustaining total parenteral nutrition (TPN) with additional supplemental intravenous (IV) fluids, termed total parenteral support, which is the standard of care for MVID, for up to 7 days a week greater than 50% of the time each day to provide adequate nutrient and electrolyte support. While crucial for MVID patients, TPN carries a significant risk of morbidity and mortality due to infections, metabolic complications, liver and/or kidney disease, and a risk of neurodevelopmental delay. There are currently no approved drug treatments for MVID.
Based on the initial proof-of-concept findings presented last month at the 11th Annual ELITE PED-GI Congress, crofelemer's novel antisecretory mechanism of action appears to have the potential to provide a novel therapeutic option to modify the disease progression associated with intestinal failure due to MVID in pediatric patients, as evidenced by the reductions in total parenteral support and potential to improve the quality of life of MVID patients.

Jaguar Health Says First Patient Randomized In Napo's Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial To Evaluate Safety And Efficacy Of Crofelemer In Pediatric Patients With MVID

First Berlin analyst Christian Orquera initiates coverage on Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) with a Buy rating and announces Price Target of $60.

Price Target

Initiation

Analyst Ratings

First Berlin Initiates Coverage On Jaguar Health with Buy Rating, Announces Price Target of $60

<h3>Gainers</h3>
<ul>
<li>Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) stock rose 18.2% to $2.14 during Thursday's after-market session. The company's market cap stands at $104.5 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) stock increased by 13.8% to $0.41. The market value of their outstanding shares is at $10.4 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) stock increased by 13.34% to $6.2. The company's market cap stands at $4.1 million. The company's, Q1 earnings came out today. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock rose 12.02% to $6.15. The market value of their outstanding shares is at $333.8 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock increased by 9.36% to $1.81. The company's market cap stands at $2.6 million. </li>
<li>Sensus Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>) stock rose 9.22% to $5.09. The company's market cap stands at $83.4 million. The company's, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 69.4% to $0.01 during Thursday's after-market session. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares decreased by 24.74% to $43.99. The company's market cap stands at $8.2 billion. As per the press release, Q4 earnings came out today. </li>
<li>Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) stock fell 24.32% to $16.0. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) shares declined by 10.98% to $0.24. The company's market cap stands at $12.3 million. </li>
<li>Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares declined by 8.99% to $2.33. The market value of their outstanding shares is at $477.7 million. As per the news, the Q1 earnings report came out today. </li>
<li>Q32 Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) stock declined by 8.05% to $1.6. The market value of their outstanding shares is at $19.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CABA

DOCS

MHUA

QTTB

SRTS

TSHA

TVTX

12 Health Care Stocks Moving In Thursday's After-Market Session

Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) reported quarterly losses of $(16.70) per share which beat the analyst consensus estimate of $(18.00) by 7.22 percent. This is a 80.83 percent increase over losses of $(87.12) per share from the same period last year. The company reported quarterly sales of $2.21 million which missed the analyst consensus estimate of $2.82 million by 21.52 percent. This is a 5.83 percent decrease over sales of $2.35 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Jaguar Health Q1 EPS $(16.70) Beats $(18.00) Estimate, Sales $2.21M Miss $2.82M Estimate

ACOG

AENT

AIRI

AMAT

AREN

BABA

BCLI

BEKE

BFRI

BHST

BIRK

BLIN

BNZI

BRAG

BTBT

BTDR

CAVA

CSIQ

CYCC

DFLI

DTIL

DTST

DUOT

EDAP

EDBL

FLNT

FTLF

GAMB

GAME

GLOB

GORV

GOSS

GSX Techedu Inc. American Depositary Shares

GOTU

HAFN

IMCC

INKT

IVVD

KORE

KPLT

KULR

LFWD

LGCY

LMFA

LPTH

LTRN

MITQ

MRSN

NICE

NRXP

NTES

NVVE

NXPL

OMER

ONDS

ORGN

PAVM

PHGE

PIII

PLBY

POCI

PPSI

PVLA

QUBT

RIME

RNXT

ROLR

SANW

SCWO

SIDU

SNYR

SOBO

SPCE

SRXH

SWKH

TIVC

TLSI

TRAK

TSSI

Earnings Scheduled For May 15, 2025

631,922 Shares of Common Stock Issuable Upon the Conversion of Outstanding Notes
622,584 Shares of Common Stock Issuable Upon the Exercise of Outstanding Common Warrants
37,376 Shares of Common Stock Issuable Upon the Exercise of Outstanding Placement Agent Warrants
This prospectus relates to the resale of up to 1,291,882 shares of Jaguar Health, Inc. (the "Company," "we," "our" or "us") voting common stock, par value $0.0001 per share (the "Common Stock"), by the Selling Stockholders listed in this prospectus (the "Selling Stockholders"). The shares of Common Stock registered for resale pursuant to this prospectus consist of (i)&nbsp;631,922 shares of Common Stock (the "Conversion Shares") issuable upon the conversion of the 6% convertible promissory notes (the "Notes"), (ii)&nbsp;622,584 shares of Common Stock (the "Common Warrant Shares") issuable upon the exercise of common warrants (the "Common Warrants"), and (iii)&nbsp;37,376 shares of Common Stock (the "Placement Agent Warrant Shares," and together with the Common Warrant Shares, the "Warrant Shares") issuable upon the exercise of certain warrants issued to our placement agent (the "Placement Agent Warrants" and together with the Common Warrants, the "Warrants"). The Notes and Warrants were issued to the Selling Stockholders in a private placement offering (the "Private Placement") that closed on March&nbsp;31, 2025.
For additional information about the Private Placement, see "Private Placement."
The Notes are immediately convertible, at each holder's option, in part or in full, into Conversion Shares at a conversion price of $5.535 per share for holders who are not an officer, director, employee or consultant of the Company (collectively, a "Company Insider"), and $5.555 per share for holders who are Company Insiders. The Common Warrants have an exercise price of $5.41 per share for holders who are not Company Insiders, and $5.43 per share for holders who are Company Insiders, and are exercisable immediately upon issuance and will expire on the earlier of (i)&nbsp;five years from the date of issuance, (ii)&nbsp;the consummation of a fundamental transaction and (iii)&nbsp;the consummation of a liquidation event. The Placement Agent Warrants have substantially the same terms as the Warrants, except that the Placement Agent Warrants have an exercise price of $6.9188 per share.

Jaguar Health Registers 1.29M Shares Of Common Stock For Resale From Private Placement That Closed On March 31, 2025, Including Shares Issuable From Convertible Notes, Common Warrants, And Placement Agent Warrants

<h3>Gainers</h3>
<ul>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares increased by 45.1% to $4.15 during Wednesday's after-market session. The company's market cap stands at $3.4 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares increased by 15.64% to $0.2. The company's market cap stands at $5.1 million. </li>
<li>Ainos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>) stock rose 13.18% to $0.6. The market value of their outstanding shares is at $9.2 million. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock increased by 13.16% to $0.28. The company's market cap stands at $1.4 million. </li>
<li>Auna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AUNA#NYSE">AUNA</a>) shares rose 11.43% to $7.7. The market value of their outstanding shares is at $569.8 million. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) shares rose 10.08% to $1.31. The market value of their outstanding shares is at $21.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) shares declined by 7.5% to $2.21 during Wednesday's after-market session. The company's market cap stands at $10.9 million. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) shares fell 7.31% to $0.19. The market value of their outstanding shares is at $4.8 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) stock declined by 6.95% to $11.39. The market value of their outstanding shares is at $7.6 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) shares declined by 6.94% to $0.31. The market value of their outstanding shares is at $19.2 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares fell 6.46% to $0.29. The company's market cap stands at $11.5 million. </li>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) stock fell 6.26% to $5.55. The market value of their outstanding shares is at $201.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIMD

AUNA

BDMD

GCTK

IRIX

NAOV

PASG

PCSA

PLRZ

12 Health Care Stocks Moving In Wednesday's After-Market Session

Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results from the proof-of-concept study of crofelemer for MVID and SBS-IF presented April 26 at the <a href="https://pr.report/9xgt">Annual ELITE PED-GI Congress</a>; Click <a href="https://pr.report/9xgu">here</a> to register
There are no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management including total parenteral nutrition (TPN) - which carries the risk of morbidity, infections, metabolic complications, liver and kidney problems, and neurodevelopmental delay
This proof-of-concept data in MVID supports crofelemer's potential inclusion in the European Medicines Agency's (EMA) <a href="https://pr.report/9xgv">PRIME</a> program for expediated and assisted regulatory approval in the EU as well as FDA's <a href="https://pr.report/9xgw">Breakthrough Therapies</a> program for expedited regulatory approval in the US
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 30, 2025 / <a href="https://pr.report/9xgb">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) family companies <a href="https://pr.report/9xgd">Napo Pharmaceuticals</a> (Napo) and <a href="https://pr.report/9xge">Napo Therapeutics</a> today announced initial proof-of-concept results showing that a novel liquid formulation of crofelemer reduced the required TPN and/or supplementary intravenous fluids, collectively referred to as parenteral support (PS) in patients with intestinal failure due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) by up to 27% and 12.5% respectively. In addition, this data showed that crofelemer reduced stool volume output and/or frequency of watery stools, and increased urine output - an indicator of improved nutrient oral absorption.

Jaguar Health Announces Initial Proof-Of-Concept Results Showing That Novel Liquid Formulation Of Crofelemer Reduced Required TPN And/Or Supplementary Intravenous Fluids In MVID And SBS-IF Patients

The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for crofelemer for MVID; Click <a href="https://viavid.webcasts.com/starthere.jsp?ei=1718118&amp;tp_key=02fe2f82c4">here</a> to register
There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management
This data was presented at the <a href="https://www.elite-pedgi.com/">Annual ELITE PED-GI Congress</a> by Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology and the primary investigator for this study

Events

Jaguar Health To Present Initial Results From Proof-of-Concept Study of Crofelemer For Rare Diseases Microvillus Inclusion Disease And Short Bowel Syndrome With Intestinal Failure

<h3>Gainers</h3>
<ul>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) stock increased by 61.0% to $12.98 during Friday's regular session. The company's market cap stands at $8.7 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares increased by 42.96% to $2.26. The company's market cap stands at $31.0 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares rose 23.66% to $0.28. The market value of their outstanding shares is at $3.9 million. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) stock rose 15.48% to $7.68. The market value of their outstanding shares is at $45.5 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock rose 15.06% to $3.97. The company's market cap stands at $2.1 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock rose 14.45% to $0.53. The market value of their outstanding shares is at $2.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) shares declined by 36.9% to $7.86 during Friday's regular session. The company's market cap stands at $25.4 million. </li>
<li>Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock fell 36.76% to $23.21. The company's market cap stands at $17.1 billion. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares fell 33.66% to $0.6. The company's market cap stands at $9.0 million. </li>
<li>VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) stock declined by 23.75% to $1.43. The company's market cap stands at $21.1 million. </li>
<li>Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) stock decreased by 21.4% to $1.02. The company's market cap stands at $85.6 million. </li>
<li>Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) stock declined by 21.1% to $15.47. The market value of their outstanding shares is at $101.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COEP

INTS

NDRA

RBOT

SMMT

STRO

SXTC

VYNE

12 Health Care Stocks Moving In Friday's Intraday Session

Press Releases

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Presenting on Emerging Growth Conference 83 Day 1 on June 17; Register to live stream

Presenting on Emerging Growth Conference 83 Day 2 on June 18; Register to live stream

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer

Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient

Comments

Jaguar Health

Notizie

Ultime notizie per Jaguar Health (NASDAQ:JAGX) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO